Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Joi + Blokes vs OurView Health

Joi + Blokes
Graded #203

Lower grade

vs+1.5
OurView Health
Graded #162

Higher grade

The verdict

OurView Health takes it — 67.6/100 to 66.1/100, but only just.

OurView Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. OurView (OurView Health) is a 100% online multi-vertical telehealth service with an Our View Savings Club membership offering pharmacy-direct pricing on U.S.-compounded medications. Joi + Blokes is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueOurView Health +26
50
76
Dose & formulationEven
64
64
Clinical oversightJoi + Blokes +7
86
79
Labs & monitoringJoi + Blokes +34
87
53
FulfillmentJoi + Blokes +5
75
70
Contract termsOurView Health +25
20
45
Joi + Blokes · left barOurView Health · right bar

The numbers

MetricJoi + BlokesOurView Health
WeighScore66.1/10067.6/100
GradeCC
Scorecard rank#203#162
Semaglutide$199/mo (promotional rate, quarterly plan, compounded)$75/mo (starting dose, compounded)
Tirzepatide$299/mo (quarterly plan, compounded)$135/mo (starting dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Joi + Blokes

Graded #203 · C

Strengths

  • Separate programs for women (Joi) and men (Blokes) — most GLP-1 telehealth is gender-agnostic
  • Trustpilot 4.6/5 from 1,254+ reviews — among the strongest review signals in the category
  • Monthly price includes medication, dosing support, clinician consults, and health coaching
  • Integrated hormone + GLP-1 programs help patients on testosterone or perimenopausal protocols
  • First-month discount ($99 sema / $149 tirz) lowers the barrier to trying GLP-1s

Where it loses points

  • Billed quarterly — a 3-month commitment up front, not month-to-month
  • Different pricing in NY and NJ — verify your state's cost before committing
  • Per-state availability isn't listed; it's zip-code gated behind signup
  • Months 2+ cost more ($199 sema / $299 tirz) than the headline intro price
  • No FDA-approved Wegovy — compounded only on the GLP-1 side; Zepbound carries a separate visit fee
OurView Health

Graded #162 · C

Strengths

  • Low starting prices via the Savings Club — compounded semaglutide from $75, tirzepatide from $135
  • Clear product pricing with no contracts; medication shipped to your door (30-day supply)
  • Full legal suite published (Terms, Privacy, HIPAA Notice, Returns & Refunds)
  • Discloses meds are compounded by a licensed third-party pharmacy; multi-vertical (TRT, HRT, BHRT, peptides)

Where it loses points

  • A comparison table on the site quotes $90 'without membership' against $75 'with membership' while the product cards say 'No membership' and the cart charges $75 without one — the provider contradicts itself on whether a membership exists
  • Both figures are starting-dose rates; the cost of a titrated dose is published as a ladder rather than a single price
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard